{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:23:19Z","timestamp":1790634199912,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ejca.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T05:09:03Z","timestamp":1559624943000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation\u2013positive metastatic melanoma treated with vemurafenib \u00b1 cobimetinib"],"prefix":"10.1016","volume":"116","author":[{"given":"Karl","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.ejca.2019.05.002_bib1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2019.05.002_bib2","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2019.05.002_bib3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2019.05.002_bib4","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2019.05.002_bib5","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1021\/mp400403s","article-title":"Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development","volume":"10","author":"Smelick","year":"2013","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.ejca.2019.05.002_bib6","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00280-013-2164-3","article-title":"Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors","volume":"71","author":"Tan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.ejca.2019.05.002_bib7","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1177\/0091270009346061","article-title":"Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib","volume":"50","author":"Yin","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ejca.2019.05.002_bib8","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1177\/0091270009333854","article-title":"Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects","volume":"49","author":"Eley","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2019.05.002_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cllc.2014.07.005","article-title":"Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer","volume":"16","author":"Chu","year":"2015","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2019.05.002_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/clpt.2014.87","article-title":"pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development","volume":"96","author":"Zhang","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ejca.2019.05.002_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/jps.23425","article-title":"Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process","volume":"102","author":"Shah","year":"2013","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.ejca.2019.05.002_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11523-018-0564-3","article-title":"The impact of dose and simultaneous use of acid-reducing agents on the effectiveness of vemurafenib in metastatic BRAF V600 mutated melanoma: a retrospective cohort study","volume":"13","author":"Knapen","year":"2018","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2019.05.002_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2019.05.002_bib14","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2019.05.002_bib15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40262-017-0523-7","article-title":"Clinical pharmacokinetics of vemurafenib","volume":"56","author":"Zhang","year":"2017","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919302862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T22:37:06Z","timestamp":1569278226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919302862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":15,"alternative-id":["S0959804919302862"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.05.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation\u2013positive metastatic melanoma treated with vemurafenib \u00b1 cobimetinib","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}